The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease

Haematologica

Volumn 91, Issue 4, 2006, Pages 475-481

  Gallamini, Andrea ^a   Rigacci, Luigi ^b   Merli, Francesco ^c   Nassi, Luca ^b   Bosi, Alberto ^b   Capodanno, Isabella ^c   Luminari, Stefano ^d   Vitolo, Umberto ^e   Sancetta, Rosaria ^f   Iannitto, Emilio ^g   Trentin, Livio ^h   Stelitano, Caterina ⁱ   Tavera, Silvia ^a   Biggi, Alberto ^a   Castagnoli, Antonio ^b   Versari, Annibale ^c   Gregianin, Michele ^f   Pelosi, Ettore ^e   Torchio, Pierfederico ^j   Levis, Alessandro ^k  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f Ospedale SS Giovanni e Paolo   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k C Arrigo Children's Hospital   (Italy)

more..

Author keywords

Early response; FDG PET; Hodgkin's disease

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 33645998113     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990;71173-86.
2. Proctor SJ, Taylor P, Donnan P. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 1991;27:624-9.
3. Gobbi PG, Comelli M, Grignani GE, Pieresca C, Montagna G, Ascari E. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's disease (IDHD). Haematologica 1994;79:241-55.
4. Hasenclever D, Diehl V, for the International Prognostic Factors Project on advanced Hodgkin's disease. A prognostic score to predict tumor control in advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.
5. Gobbi PG, Zinzani PL, Broglia C, Comelli M, Magagnoli M, Federico M, et al. Comparison of prognostic models in patients with advanced Hodgkin's disease. Cancer 2001;91:1467-78.
6. Zander T, Wiedenmann S, Wolf J. Prognostic factors in Hodgkin's lymphoma. Ann Oncol 2002; 13(suppl. 1):67-74.
7. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002;13 Suppl 1:75-8.
8. Bonfante V, Santoro A, Viviani S, Valagussa P, Bonadonna G. ABVD in the treatment of Hodgkin's disease. Semin Oncol 1992;19 Suppl 5:38-45.
9. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
10. SAS Institute Inc. SAS/STAT user guide. Cary, NC: SAS Institute Inc, 2000.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. JAMA 1958;53:457-81.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
13. Cox DR. Regression models and life-tables. J Stat Soc 1982;34:187-220.
14. Generalized Linear Models. Cambridge, UK: Chapman and Hall University Press. 1988.
15. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin disease trial. N Engl J Med 2002:346:1417-8.
16. Duggan D, Petroni GR, Johnson JL, Glick GH, Fisher RI, Connors JM. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14.
17. Tesch H, Sieber M, Diehl V. Treatment of advanced stage Hodgkin's disease. Oncology 2001;60:101-9.
18. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D. Standard and increased-dose BEA-COPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease N Engl J Med 2003;348:2386-95.
19. Vassilakopoulos TP, Angelopopulou MK, Siakantaris MP, Kokoris SI, Pangalis GA. Hodgkin's lymphoma: treatment and prognosis. Haema 2004;7 Suppl 1:S53-63.
20. Levis A, Vitolo U, Ciocca Vasino MA, Cametti G, Urgesi A, Bertini M. Predictive value of the early response to chemotherapy in high risk stages II and III Hodgkin's disease Cancer 1987;15:1713-9.
21. Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma ana Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004;31:22-8.
22. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, et al. Serum levels of the soluble form of the CD 30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998;91:3011-6.
23. Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, et al. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 2004;45:2085-92.
24. Carde P, Koscielny S, Franklin J, Axdorph U, Raemaekers J, Diehl V, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002;13 supplement 1:86-91.
25. Font D, Bar-Shalom R, Mor M, Haim N, Epelbaum RE, Frenkel A, et al. Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. Radiology 1999;210:487-91
26. Kostakoglu L, Coleman M, Leonard J, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphomas and Hodgkin's disease. J Nucl Med 2002;43:1018-27.
27. Rigacci L, Castagnoli A, Carpaneto A, Carrai V, Vaggelli L, Matteini M. Can (18)F-FDG PET after first cycle chemotherapy predict the efficacy of therapy in Hodgkin's diseased Haematologica 2002;87:ELT 24.
28. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85-92.
29. Hutchings M, Loft A, Hansen M, Moller Pedersen L, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin's lymphoma. Blood 2006;107:52-9.
30. Zijlstra JM, Hoekstra OS, Raijmakers PG, Comans EFI, van der Hoeven JJM, Teule GJJ, et al. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2003;123:454-62.
31. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81.
32. Mikhaeel NG, Hutchings M, Fields PA, O'Doherthy MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-23.
33. Stroobants S, Verhoef G, Spaepen K. The utility of PET in managing patients with Hodgkin's lymphoma. Hematology 2004;188-94.
34. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-82.
35. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005;35:186-96.
36. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280-6.
37. Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. Cancer 2003;97:2748-59.